Abstract | PURPOSE: For patients with metastatic prostate cancer, first results have shown that rhenium-186 (Re-186) hydroxyethylidene diphosphonate ( HEDP) is efficient in pain palliation of disseminated bone metastases. The aim of this study was to determine whether significant pain reduction can also be achieved in breast cancer patients with Re-186 HEDP. METHODS: Thirty patients with breast cancer who had multifocal painful bone metastases received a total of 38 intravenous Re-186 HEDP injections. Pain relief was assessed through daily documentation of the visual analog scale and analgesic consumption. A significant response to treatment was determined if the visual analog scale or analgesic consumption decreased significantly for at least 2 weeks. Blood counts were controlled at baseline and at weeks 4 and 8. RESULTS: A response to pain therapy was observed in 60% (18 of 30) of the patients. A reversible thrombocytopenia and leukopenia of grade 2 (according to World Health Organization criteria) was found in 4 and 2 patients, respectively. CONCLUSION:
|
Authors | H Palmedo, H Bender, C Dierke-Dzierzon, U M Carl, J Risse, D Krebs, H J Biersack |
Journal | Clinical nuclear medicine
(Clin Nucl Med)
Vol. 24
Issue 9
Pg. 643-8
(Sep 1999)
ISSN: 0363-9762 [Print] United States |
PMID | 10478737
(Publication Type: Journal Article)
|
Chemical References |
- Analgesics
- Radioisotopes
- Rhenium
- Etidronic Acid
|
Topics |
- Adult
- Aged
- Analgesics
(administration & dosage)
- Blood Cell Count
- Bone Neoplasms
(blood, diagnostic imaging, secondary)
- Breast Neoplasms
(pathology)
- Etidronic Acid
(adverse effects, therapeutic use)
- Female
- Humans
- Injections, Intravenous
- Middle Aged
- Pain
(prevention & control)
- Pain Measurement
- Palliative Care
- Radioisotopes
(adverse effects, therapeutic use)
- Radionuclide Imaging
- Rhenium
(adverse effects, therapeutic use)
- Treatment Outcome
|